TrialClinical cancer research : an official journal of the American Association for Cancer Research2010

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Setsuko K Chambers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.